Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 2
2011 3
2012 5
2013 7
2014 8
2015 6
2016 13
2017 9
2018 5
2019 19
2020 15
2021 22
2022 22
2023 25
2024 40
2025 33
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects.
Greco A, Finocchiaro S, Spagnolo M, Faro DC, Mauro MS, Raffo C, Sangiorgio G, Imbesi A, Laudani C, Mazzone PM, Ammirabile N, Giacoppo D, Landolina D, Capodanno D. Greco A, et al. Circulation. 2025 Feb 11;151(6):400-415. doi: 10.1161/CIRCULATIONAHA.124.069210. Epub 2025 Feb 10. Circulation. 2025. PMID: 39928714 Free article. Review.
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proi …
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipo …
Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.
Mohammadi-Shemirani P, Chong M, Narula S, Perrot N, Conen D, Roberts JD, Thériault S, Bossé Y, Lanktree MB, Pigeyre M, Paré G. Mohammadi-Shemirani P, et al. J Am Coll Cardiol. 2022 Apr 26;79(16):1579-1590. doi: 10.1016/j.jacc.2022.02.018. J Am Coll Cardiol. 2022. PMID: 35450575 Free PMC article.
However, preventative therapies are needed with ancillary benefits on its cardiovascular comorbidities. Lipoprotein(a) (Lp[a]) is a recognized risk factor for atherosclerotic cardiovascular disease (ASCVD), which itself increases AF risk, but it remains unknown whet …
However, preventative therapies are needed with ancillary benefits on its cardiovascular comorbidities. Lipoprotein(a) (Lp[a]) …
Lipoprotein(a) and Cardiovascular Disease.
Kamstrup PR. Kamstrup PR. Clin Chem. 2021 Jan 8;67(1):154-166. doi: 10.1093/clinchem/hvaa247. Clin Chem. 2021. PMID: 33236085 Review.
CONTENT: The present review summarizes evidence of causality for high lipoprotein(a) concentrations gained from large genetic epidemiologic studies and discusses measurements of lipoprotein(a) and future treatment options for high values found in an es …
CONTENT: The present review summarizes evidence of causality for high lipoprotein(a) concentrations gained from large genetic …
Lipoprotein(a): from Causality to Treatment.
Kronenberg F. Kronenberg F. Curr Atheroscler Rep. 2024 Mar;26(3):75-82. doi: 10.1007/s11883-024-01187-6. Epub 2024 Jan 22. Curr Atheroscler Rep. 2024. PMID: 38252372 Free PMC article. Review.
PURPOSE OF REVIEW: This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future. ...Already in the early 1990s, the principle o …
PURPOSE OF REVIEW: This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disea …
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Burgess S, et al. JAMA Cardiol. 2018 Jul 1;3(7):619-627. doi: 10.1001/jamacardio.2018.1470. JAMA Cardiol. 2018. PMID: 29926099 Free PMC article.
IMPORTANCE: Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with the risk of coronary heart disease (CHD), but randomized trials of several therapies that reduce Lp(a) levels by 25% to 35% have not provided any e …
IMPORTANCE: Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with the risk of co …
Structure, function, and genetics of lipoprotein (a).
Schmidt K, Noureen A, Kronenberg F, Utermann G. Schmidt K, et al. J Lipid Res. 2016 Aug;57(8):1339-59. doi: 10.1194/jlr.R067314. Epub 2016 Apr 13. J Lipid Res. 2016. PMID: 27074913 Free PMC article. Review.
Lipoprotein (a) [Lp(a)] has attracted the interest of researchers and physicians due to its intriguing properties, including an intragenic multiallelic copy number variation in the LPA gene and the strong association with coronary heart disease (CHD). ...
Lipoprotein (a) [Lp(a)] has attracted the interest of researchers and physicians due to its intriguing properties, including a …
Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.
Björnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, Borén J. Björnson E, et al. J Am Coll Cardiol. 2024 Jan 23;83(3):385-395. doi: 10.1016/j.jacc.2023.10.039. J Am Coll Cardiol. 2024. PMID: 38233012 Free PMC article.
BACKGROUND: Lipoprotein(a) (Lp(a)) is recognized as a causal factor for coronary heart disease (CHD) but its atherogenicity relative to that of low-density lipoprotein (LDL) on a per-particle basis is indeterminate. ...In these Lp(a) and LDL clusters, the relationsh …
BACKGROUND: Lipoprotein(a) (Lp(a)) is recognized as a causal factor for coronary heart disease (CHD) but its atherogenicity re …
Lipoprotein(a).
Kronenberg F. Kronenberg F. 2021 Jul 2. In: von Eckardstein A, Binder CJ, editors. Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022. 2021 Jul 2. In: von Eckardstein A, Binder CJ, editors. Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022. PMID: 36122123 Free Books & Documents. Review.
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are explained by a single gene, the LPA gene. ...Studies that used these genetic variants as a genetic instrument to support a causal role for Lp(a …
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are exp …
Lipoprotein(a).
Kronenberg F. Kronenberg F. Handb Exp Pharmacol. 2022;270:201-232. doi: 10.1007/164_2021_504. Handb Exp Pharmacol. 2022. PMID: 34196811
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are explained by a single gene, the LPA gene. ...Studies that used these genetic variants as a genetic instrument to support a causal role for Lp(a …
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are exp …
Lipoprotein(a) and stroke: a two-sample Mendelian randomization study.
Huang Y, Zhang R, Han L, Wu Y, Deng X, Xu T, Wu Y, Gao X, Zhou C, Sun J. Huang Y, et al. Front Aging Neurosci. 2023 May 12;15:1178079. doi: 10.3389/fnagi.2023.1178079. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37251802 Free PMC article.
BACKGROUND: To evaluate the causal relationship between lipoprotein(a) Lp(a) and stroke risk. METHOD: Adopting two grand scale genome-wide association study (GWAS) databases, the instrumental variables were selected on the basis that the genetic loci met the criteri …
BACKGROUND: To evaluate the causal relationship between lipoprotein(a) Lp(a) and stroke risk. METHOD: Adopting two grand scale …
235 results